Table 5 The overall survival of biologic DMARDs
From: Treatment persistence of biologics among patients with psoriatic arthritis
| Â | 1-year survival (%) | 2-year survival (%) | 5-year survival (%) |
|---|---|---|---|
Adalimumab | 50.7 | 37 | 21.3 |
Etanercept | 56.4 | 41.2 | 23.3 |
Infliximab | 51.7 | 34 | 17.5 |
Golimumab | 55 | 40.5 | 22.5 |
Ustekinumab | 44.6 | 31.9 | 17.3 |
Secukinumab | 63.2 | 41.7 | – |